21044 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof; Hydrolases (3) acting on peptide bonds (3.4) Urokinase; Tissue plasminogen activator
TARGET-SPECIFIC THROMBOLYTIC UROKINASE MICROSPHERES AND METHOD TO DISSOLVE SICKLE DISEASE CLOTS
#2METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS
#3CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#4TARGETED THROMBOLYSIS FOR TREATMENT OF MICROVASCULAR THROMBOSIS
#5Neuroprotection and Axon Regeneration Therapies for CNS Axonopathies by Modulating Membrane Structure, Cytoskeleton and Signaling Molecules
#6METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE
#7METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS
#8COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM INJURY
#9TREATMENT FOR AIRWAY CAST OBSTRUCTION
#10DRUG REGIMEN FOR TREATMENT OF CEREBRAL ISCHEMIA
#11THROMBOLYTIC MICROSPHERES TO DISSOLVE VASO-OCCLUSIVE CLOTS
#12METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS
#13CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#14CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#152-IMINOBIOTIN FOR USE IN THE TREATMENT OF STROKE
#16CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#17METHODS OF TREATING A SUBJECT EXPOSED TO A TOXIC INHALED CHEMICAL WITH MESNA
#18TREATMENT OF AN IOP CONDITION
#19TISSUE PLASMINOGEN ACTIVATOR FORMULATION
#20USE OF PERLECAN AND FRAGMENTS THEREOF TO REDUCE THE RISK OF DEATH IN STROKE PATIENTS
#21SLOW RELEASE PLASMINOGEN ACTIVATOR FORMULATION FOR USE IN THE TREATMENT OF THROMBOTIC OR HAEMORRHAGIC DISEASE
#22DODECAFLUOROPENTANE EMULSION AS A STROKE AND ISCHEMIA THERAPY
#23MEDICAL USE OF ICARITIN
#24INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF
#25METHOD AND DRUG FOR PREVENTING AND TREATING MULTIPLE SCLEROSIS
#26METHOD AND DRUG FOR TREATING VIRAL PNEUMONIA
#27PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF
#28Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injury
#29CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#30TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS
#31METHODS FOR SAFE AND EFFECTIVE THROMBOLYSIS USING SEQUENTIAL ADMINISTRATION OF TISSUE PLASMINOGEN ACTIVATOR AND MUTANT PRO-UROKINASE
#32Treatment for airway cast obstruction
#33METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS
#34USE OF EXTRACELLULAR VESICLES IN COMBINATION WITH TISSUE PLASMINOGEN ACTIVATOR AND/OR THROMBECTOMY TO TREAT STROKE
#35Compositions and methods for treating central nervous system injury
#36Drug regimen for treatment of cerebral ischemia
#37POLYPEPTIDE THERAPEUTICS AND USES THEREOF
#38Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia
#39Combination therapy for ischemia
#40THROMBOLYTIC MICROSPHERES TO DISSOLVE VASO-OCCLUSIVE CLOTS
#41Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#42CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO
#43Heteromultivalent particle compositions
#44Methods for thrombolysis
#45Targeted Thrombolysis for Treatment of Microvascular Thrombosis
#46Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
#47METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY
#48METHODS OF TREATING STROKE
#49Glaucoma treatment
#50Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
#51Drug regimen for treatment of cerebral ischemia
#52Inhibition of vascular matrix metalloproteinase-9 to treat ischemic injury
#53Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
#54THERAPEUTIC AND PROPHYLACTIC METHODS, USES AND COMPOSITIONS COMPRISING ANNEXIN A5
#55PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF
#56POLYPEPTIDE THERAPEUTICS AND USES THEREOF
#57THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF
#58METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
#59E-WE THROMBIN ANALOG AND FIBRINOLYTIC COMBINATION
#60METHODS AND COMPOSITIONS FOR MODULATING FGF23 LEVELS
#61Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#62Treatment for airway cast obstruction
#63Composition comprising uric acid for the treatment treated with mechanical thrombectomy
#64METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY
#65Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
#66Compositions and methods for administration of an enzyme to a subject's airway
#67Compositions and methods for treating central nervous system injury
#68Use of serine protease inhibitors in the treatment of skin diseases
#69Methods of medical treatment with SUR1-TRPM4 channel inhibitors
#70METHOD FOR PREVENTING OR TREATING LIVER TISSUE DAMAGE AND ASSOCIATED DISEASES
#71GRP78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents
#72A device for ultrasonic-accelerated hematoma lysis or thrombolysis of intracerebral or intraventricular hemorrhages or hematomas
#73Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#74Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#75Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#76Polypeptides and polypeptide constructs comprising single domain antibodies directed against von willebrand factor
#77Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#78METHODS OF TREATING STROKE
#79Combination therapy for ischemia
#80PROTEIN KINASE C INHIBITION TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT FOR ISCHEMIC DISEASE
#81Methods of treating a subject for a condition
#82Peptide-based methods for treating neurological injury
#83Method of treating diabetic nephropathy comprising administering plasminogen
#84Cell therapy for the treatment of neurodegeneration
#85Heteromultivalent particle compositions
#86Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase
#87Method and composition for enhancing the delivery of anti-platelet drugs for the treatment of acute stroke
#88Compositions and methods for treating cardiovascular related disorders
#89Combination of TAFIa inhibitor with plasminogen activator
#90Method of treating stroke by administering a compound that inhibits VEGF-B signaling in combination with a thrombolytic agent
#91Drug regimen for treatment of cerebral ischemia
#92Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
#93METHODS FOR TREATING RESTENOSIS USING ANNEXIN A5
#94SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES
#95POLYPEPTIDE THERAPEUTICS AND USES THEREOF
#96Dodecafluoropentane emulsion as a stroke and ischemia therapy
#97THERAPEUTIC AND PROPHYLACTIC METHODS, USES AND COMPOSITIONS COMPRISING ANEXIN A5
#98Methods and pharmaceutical compositions for the treatment of ischemic conditions
#99Cell therapy for the treatment of neurodegeneration
#100Methods for treatment of stroke or cerebrovascular accidents using an ETreceptor agonist
#101PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF
#102STABLE INJECTABLE COMPOSITION OF PHARMACEUTICALLY ACTIVE AGENTS AND PROCESS FOR ITS PREPARATION
#103Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
#104Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
#105Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
#106NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE
#107Gelatinase inhibitors and prodrugs
#108Aminofucoidan as a vector for fibrinolysis in thrombotic diseases
#109COMPOSITIONS AND METHODS FOR ADMINISTRATION OF AN ENZYME TO A SUBJECT'S AIRWAY
#110Methods for treating restenosis using annexin A5
#111Compounds and methods for the treatment of vascular disease
#112PKC activators and anticoagulant in regimen for treating stroke
#113Heteromultivalent particle compositions
#114Glaucoma treatment
#115Treatment for airway cast obstruction
#116Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
#117Diagnostic marker for treatment of cerebral ischemia
#118Gelatinase inhibitors and prodrugs
#119Aegyptin and uses thereof
#120Compounds and methods for the treatment of vascular disease
#121C-terminally tethered amino acids and their fibrinolytic therapeutic uses
#122USE OF SERINE PROTEASE INHIBITORS IN THE TREATMENT OF SKIN DISEASES
#123Pharmaceutical compositions and methods for digesting atherosclerotic plaques
#124Combination therapy for ischemia
#125Modified MT-SP1 proteases that inhibit complement activation
#126Annexin A2 and tissue plasminogen activator for treating vascular disease
#127Chimeric neuregulins and method of making and use thereof
#128Cell therapy for the treatment of neurodegeneration
#129Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
#130NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE
#131Methods for treatment of stroke or cerebrovascular accidents using an ETreceptor agonist
#132Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
#133Compositions and methods of use of phorbol esters for the treatment of stroke
#134Pharmaceutical composition for treating ischemic events
#135Chimeric neuregulins and method of making and use thereof
#136Chimeric neuregulins and method of making and use thereof
#137Methods of treating a subject for a condition
#138Heteromultivalent nanoparticle compositions
#139Treatment of acute ischemic stroke or intracranial bleeding with tPa and carbamylated erythropoietin
#140PROCESS FOR INHIBITION OF CEREBRAL DAMAGE ASSOCIATED WITH ISCHEMIA BY ANTHOCYANINS AND ANTHOCYANIDINS
#141METHODS FOR THE PREVENTION OR TREATMENT OF VESSEL OCCLUSION INJURY
#142Aegyptin and uses thereof
#143Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
#144TREATMENT OF NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS
#145Gelatinase inhibitors and prodrugs
#146NON-NEUROTOXIC PLASMINOGEN ACTIVATING FACTORS FOR TREATING OF STROKE
#147METHODS TO FACILITATE TRANSMISSION OF LARGE MOLECULES ACROSS THE BLOOD-BRAIN, BLOOD-EYE, AND BLOOD-NERVE BARRIERS
#148SYSTEMS AND METHODS FOR TREATING POST-OPERATIVE, ACUTE, AND CHRONIC PAIN USING AN INTRA-MUSCULAR CATHETER ADMINISTRATED COMBINATION OF A LOCAL ANESTHETIC AND A NEUROTOXIN PROTEIN
#149Tissue plasminogen activator variant uses
#150Modified proteases that inhibit complement activation
#151METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOEITIC GROWTH FACTORS
#152Pharmaceutical composition for treating ischemic events
#153CROSS-ß STRUCTURE COMPRISING AMYLOID-BINDING PROTEINS AND METHODS FOR DETECTION OF THE CROSS-ß STRUCTURE, FOR MODULATING CROSS-ß STRUCTURES FIBER FORMATION AND FOR MODULATING CROSS-ß STRUCTURE-MEDIATED TOXICITY
#154Method of treating stroke with tenecteplase
#155Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma
#156Neutrophil-depleted platelet rich plasma formulations for cardiac treatments
#157Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist
#158DICHLORACETATE IN COMBINATION WITH CLINICALLY HIGH LEVELS OF CARDIOPROTECTIVE OR HEMODYNAMIC DRUGS
#159Method of treating thrombocytopenia
#160PKC activators and anticoagulant in regimen for treating stroke
#161FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE
#162DAG-TYPE AND INDIRECT PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE
#163Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke
#164SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME
#165Compounds and methods for treatment of stroke
#166Method of using prourokinase in facilitated percutaneous coronary intervention in patients with acute myocardial infarction
#167Keratin biomaterials for treatment of ischemia
#168INTRAVENTRICULAR HEMORRHAGE THROMBOSIS
#169METHODS OF TREATING THROMBOEMBOLIC DISORDERS
#170Aegyptin and uses thereof
#171USE OF SERINE PROTEASE INHIBITORS IN THE TREATMENT OF SKIN DISEASES
#172COMPOSITIONS AND METHODS FOR TREATING VASCULAR DISEASE
#173Use of matrix metalloproteinase-10 (MMP-10) for thrombolytic treatments
#174C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
#175Use of Urokinase Type Plasminogen Activator Inhibitors for the Treatment of Corneal Disorders
#176METHODS AND AGENTS MODULATING UPA/UPAR ACTIVITY
#177tPA mutant in the treatment of acute brain injury and neurodegenerative disorders
#178Methods for treating restenosis using annexin A5
#179PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS
#180METHOD AND COMPOSITION FOR REDUCING REPERFUSION INJURY
#181Compounds and methods for the treatment of vascular disease
#182MICRO- AND NANOSCALE DEVICES FOR DELIVERY OF ACTIVE FIBRONOLYTIC AGENTS
#183NOVEL PATIENT SUBGROUPS FOR THROMBOLYSIS
#184Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
#185COMBINATION TREATMENT WITH t-PA VARIANT AND LOW MOLECULAR WEIGHT HEPARIN
#186SYSTEMS AND METHODS FOR TREATING POST- OPERATIVE, ACUTE, AND CHRONIC PAIN USING AN INTRA-MUSCULAR CATHETER ADMINISTRATED COMBINATION OF A LOCAL ANESTHETIC AND A NEUROTOXIN PROTEIN
#187Means and methods for the recruitment and identification of stem cells
#188USE OF COAGULATION PROTEINS TO LYSE CLOTS
#189Composition And Methods Involving Thrombolytic Agents
#190ANTI-HIV AGENTS
#191Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
#192METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOEITIC GROWTH FACTORS
#193Platelet rich plasma formulations for cardiac treatments
#194Method for preparation of hepatocyte using ES cell
#195COMBINATION THERAPY FOR INHIBITION OF PLATELET AGGREGATION
#196USE OF MATRIX METALLOPROTEINASE-10 (MMP-10) FOR THROMBOLYTIC TREATMENTS
#197Methods and compositions for treating platelet-related disorders
#198Identifying and modulating molecular pathways that mediate nervous system plasticity
#199COMBINATION DRUGS COMPRISING VEGF INHIBITOR AND SERINE PROTEASES/THROMBOLYTIC COMPOUNDS FOR TREATING NEOVASCULAR DISORDERS
#200Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke
#201Non-neurotoxic plasminogen activating factors for treating of stroke
#202CELL-SURFACE DECORATION WITH ACTIVE AGENTS
#203Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow
#204DICHLOROACETATE IN COMBINATION WITH CLINICALLY HIGH LEVELS OF CARDIOPROTECTIVE OR HEMODYNAMIC DRUGS
#205Therapeutic methods that target the NCchannel
#206Methods of treating neurological conditions with hematopoeitic growth factors
#207Remedy for and Method of Treating Ischemic Cerebral Stroke
#208C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
#209Combination Treatment with t-PA Variant and Low Molecular Weight Heparin
#210Non-neurotoxic plasminogen activating factors for treating stroke
#211Targeting vector to the urokinase plasminogen activator receptor
#212Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage
#213Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
#214Medical Devices and Coatings Therefor
#215METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOEITIC GROWTH FACTORS
#216Cross-β structure comprising amyloid-binding proteins and methods for detection of the cross-β structure, for modulating cross-β structures fiber formation and modulating cross-β structure-mediated toxicity
#217Methods of treating neurological conditions with hematopoeitic growth factors
#218Botulinum toxin compositions and methods
#219Botulinum toxin compositions and methods
#220METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOEITIC GROWTH FACTORS
#221Methods of treating neurological conditions with hematopoeitic growth factors
#222Methods for treating conditions associated with the accumulation of excess extracellular matrix
#223NEUROPROTECTION BY BLOOD FLOW STABILIZATION
#224METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOEITIC GROWTH FACTORS
#225SUPPRESSION OF INHIBITORS
#226Methods and compositions for treating platelet-related disorders
#227USE OF A VECTOR COMPRISING A NUCLEIC ACID ENCODING AN ANTI-ANGIOGENIC FACTOR FOR THE TREATMENT OF CORNEAL NEOVASCULARIZATION
#228METHOD OF TREATING STROKE WITH THROMBOLYTIC AGENT
#229Kappam-conopeptides as organ protectants
#230Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
#231Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
#232C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis
#233C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
#234Cytoprotective therapeutic agents for the prevention of reperfusion injury following ischemic stroke
#235TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
#236Compounds and methods for treatment of stroke
#237Use of nitric oxide adducts
#238Pharmaceutical combined preparation containing a therapeutic protein
#239Agent for treatment of cerebral ischemic diseases
#240Compounds that inhibit caspase activity for treating glaucoma
#241Anti-HIV agents
#242Coated catheters
#243TREATMENT FOR EMBOLIC STROKE
#244Method for increasing the serum half-life of a biologically active molecule
#245Modified proteases that inhibit complement activation
#246Combination therapy for inhibition of platelet aggregation
#247Method for increasing the serum half-life of a biologically active molecule
#248Method for preventing and/or treating neurodegenerative diseases
#249Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs
#250Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses
#251PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS
#252Use of coagulation proteins to lyse clots
#253Methods and compositions for protection against thrombolysis associated reperfusion injury
#254Kappa-PVIIA-related conotoxins as organ protectants
#255Catheter Composition and Uses Thereof
#256Inhibitors for use in hemostasis
#257Catheter composition and uses thereof
#258Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism
#259Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses
#260Method for reducing obstructive hydrocephalus
#261Means and methods for the recruitment and identification of stem cells
#262Combination treatment with t-PA variant and low molecular weight heparin
#263Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
#264Detection and treatment of intravascular lesions
#265Non-neurotoxic plasminogen activating factors for treating of stroke
#266Compositions and methods for selective dissolution of nascent intravascular blood clots
#267Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
#268Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
#269Methods and compositions for generating angiostatin
#270Intraventricular hemorrhage thrombolysis
#271Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
#272Cross-beta structure comprising amyloid-binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity
#273Methods of treating a subject for a condition
#274Lung volume reduction using glue composition
#275Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
#276Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
#277Combination treatment for acute myocardial infarction
#278Protease activity of thrombin inhibits angiogenesis
#279Methods and compositions for treating platelet-related disorders
#280Method for increasing the serum half-life of a biologically active molecule
#281Non-antigenic stabilizer and physiologically active substance
#282Compositions and methods for modulating muscle cell and tissue contractility
#283Implantable system with drug-eluting cells for on-demand local drug delivery
#284Methods of treating neurological conditions with hematopoietic growth factors
#285Methods for treating conditions associated with the accumulation of excess extracellular matrix
#286Stent lining
#287Antithrombotic materials and methods
#288Non-neurotoxic plasminogen activating factors for treating stroke
#289Methods for treating conditions associated with the accumulation of excess extracellular matrix
#290Media indexer
#291Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof